9-(4-bromonaphthalen-1-yl)-10-phenylanthracene

We are 9-(4-bromonaphthalen-1-yl)-10-phenylanthracene CAS:1062556-32-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:9-(4-bromonaphthalen-1-yl)-10-phenylanthracene
CAS.NO:1062556-32-4
Synonyms:PA1NBA-B
9-(4-bromonaphthalen-1-yl)-10-phenylanthracene
9-(4-bromo-1-naphthalenyl)-10-phenyl- Anthracene
Molecular Formula:C30H19Br
Molecular Weight:459.37586
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

9-(4-bromonaphthalen-1-yl)-10-phenylanthracene


Related News: On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.Linoleato de etilo (ENE) CAS:544-35-4 On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.methyl (E)-2-(2-hydroxyphenyl)-3-methoxyprop-2-enoate Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).2-bromo-9,9-dimetil-10-fenil-9,10-dihidroacridina CAS:1319720-64-3 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
Tetraethylammonium bromide View Details
2,3-Dimercaptobutane View Details
N-OCTYL ACRYLATE View Details
2-Bromo-4-fluoronitrobenzene manufacturer 2-Fluoro-6-methylpyridine manufacturer 3,4-Dihydro-7-(4-bromobutoxy)-2(1H)-quinolinone manufacturer (4R,6R)-tert-Butyl-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate manufacturer 2-Fluoro-1,3-dimethylimidazolidinium hexafluorophosphate manufacturer